Effect of <italic style="font-style: italic">Linggui Zhugan Decoction </italic>（苓桂术甘汤） on Reprogramming of Liver Fatty Acid Metabolism in Mice Model of Hepatocellular Carcinoma Associated with Non-alcoholic Fatty Liver

CAO Huimin; KONG Liang; SUI Guoyuan; LENG Xue; CHEN Wenna; JIA Lianqun

doi:10.13288/j.11-2166/r.2023.13.013

您当前的位置：

首页 >

文章列表页 >

Effect of Linggui Zhugan Decoction （苓桂术甘汤） on Reprogramming of Liver Fatty Acid Metabolism in Mice Model of Hepatocellular Carcinoma Associated with Non-alcoholic Fatty Liver

更新时间：2023-06-30

- Effect of Linggui Zhugan Decoction （苓桂术甘汤） on Reprogramming of Liver Fatty Acid Metabolism in Mice Model of Hepatocellular Carcinoma Associated with Non-alcoholic Fatty Liver
- Journal of Traditional Chinese Medicine Vol. 64, Issue 13, Pages: 1366-1374(2023)
- 作者机构：
  
  1.辽宁中医药大学中医脏象理论及应用教育部重点实验室，辽宁省沈阳市皇姑区崇山东路79号，110847
  2.辽宁中医药大学医学检验学院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2023.13.013
  CLC：
- Received：25 October 2022，
  
  Revised：2023-02-27，
  
  Published：02 July 2023
- 稿件说明：
移动端阅览
曹慧敏,孔亮,隋国媛等.苓桂术甘汤对非酒精性脂肪肝相关肝细胞癌模型小鼠肝脂肪酸代谢重编程的影响[J].中医杂志,2023,64(13):1366-1374.

CAO Huimin,KONG Liang,SUI Guoyuan,et al.Effect of Linggui Zhugan Decoction （苓桂术甘汤） on Reprogramming of Liver Fatty Acid Metabolism in Mice Model of Hepatocellular Carcinoma Associated with Non-alcoholic Fatty Liver[J].Journal of Traditional Chinese Medicine,2023,64(13):1366-1374.
曹慧敏,孔亮,隋国媛等.苓桂术甘汤对非酒精性脂肪肝相关肝细胞癌模型小鼠肝脂肪酸代谢重编程的影响[J].中医杂志,2023,64(13):1366-1374. DOI： 10.13288/j.11-2166/r.2023.13.013.

CAO Huimin,KONG Liang,SUI Guoyuan,et al.Effect of Linggui Zhugan Decoction （苓桂术甘汤） on Reprogramming of Liver Fatty Acid Metabolism in Mice Model of Hepatocellular Carcinoma Associated with Non-alcoholic Fatty Liver[J].Journal of Traditional Chinese Medicine,2023,64(13):1366-1374. DOI： 10.13288/j.11-2166/r.2023.13.013.

摘要

目的

从肝脂肪酸代谢重编程角度探讨苓桂术甘汤治疗非酒精性脂肪肝相关肝细胞癌（NAFLD-HCC）的可能作用机制。

方法

将60只C57BL/6小鼠随机分为正常组、脂肪肝组、脂肪肝相关肝癌组以及苓桂术甘汤低、中、高剂量组，每组10只。脂肪肝相关肝癌组及苓桂术甘汤低、中、高剂量组小鼠采用腹腔注射二乙基亚硝胺和高脂饲料喂养相结合方式建立NAFLD-HCC模型；脂肪肝组小鼠采用高脂饲料喂养建立非酒精性脂肪性肝病模型；正常组予普通饲料喂养。造模成功后，苓桂术甘汤低、中、高剂量组小鼠分别给予苓桂术甘汤4.875、9.750、19.500 g/（kg·d）灌胃，正常组、脂肪肝组、脂肪肝相关肝癌组小鼠每天给予10 ml/kg生理盐水灌胃，各组均连续灌胃30天。检测各组小鼠血脂含量［包括甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）］及肝脏游离脂肪酸（FFA）含量，HE及油红O染色观察小鼠肝脏组织病理学改变；检测各组小鼠血清甲胎蛋白（AFP）、癌胚抗原（CEA）含量及肝脏肿瘤增殖抗原Ki-67蛋白表达，肝脏脂蛋白脂肪酶（LPL）、白细胞分化抗原36（CD36）、肉毒碱棕榈酰基转移酶1α（ CPT1α）、B淋巴细胞瘤-2基因（Bcl-2）、Bcl-2相关X蛋白（Bax）蛋白表达，LPL、CD36、CPT1α mRNA表达。

结果

与正常组比较，脂肪肝相关肝癌组小鼠肝脏炎性细胞浸润，脂肪变性明显，部分细胞出现小细胞性增生的病理改变，血清TC、TG、LDL-C、AFP、CEA含量升高，HDL-C含量下降（

＜0.05或

＜0.01），肝脏Ki-67蛋白、Bcl-2蛋白表达均升高，LPL、CD36、CPT1α mRNA及蛋白表达升高（

＜0.05或

＜0.01）；脂肪肝组仅血清TC、TG和LDL-C含量升高，病理显示肝脏组织仅有脂肪变性和炎细胞浸润，AFP、CEA含量及肝脏Ki-67蛋白表达差异无统计学意义（

＞0.05）。与脂肪肝相关肝癌组比较，苓桂术甘汤高剂量组可显著改善肝脏病理形态，显著降低肝脏脂质沉积面积，降低血清TC、TG、LDL-C、AFP、CEA含量，升高HDL-C含量，降低肝脏Ki-67、Bcl-2蛋白表达和LPL、CD36、CPT1α蛋白及mRNA表达（

＜0.05或

＜0.01）；苓桂术甘汤中、低剂量组上述各指标改善效果不及高剂量组。

结论

苓桂术甘汤可能通过影响LPL/CD36/CPT1信号轴调控脂肪酸代谢重编程，从而抑制NAFLD-HCC的发生发展。

Abstract

Objective

To observe the potential mechanism of

Linggui Zhugan Decoction

（苓桂术甘汤， LZD） in the treatment of nonalcoholic fatty liver disease-associated hepatocellular carcinoma （NAFLD-HCC） from fatty acid metabolism reprogramming.

Methods

Sixty C57BL/6 mice were randomly divided into normal group， NAFLD group， NAFLD-HCC group， low-， medium- and high-dose LZD groups， with 10 mice in each group.NAFLD-HCC mouse models were established by intraperitoneal injection of diethylnitrosamine（DEN）combined with a high-fat diet（HFD） in the NAFLD-HCC group， low-， medium- and high-dose LZD groups，while NAFLD models were made through HFD in the NAFLD group； the mice in the normal group were fed with normal diet. After the model was successfully established，low-， medium- and high-dose LZD groups were intragastrically administered with 4.875， 9.750 and 19.500 g/（kg·d） of LZD solutions， respectively， while the other groups were intragastrically administered with 10ml/kg of normal saline， all for 30 days. The levels of blood lipid indicators including triglyceride （TG）， total cholesterol （TC）， low-density lipoprotein cholesterol （LDL-C） and high-density lipoprotein cholesterol （HDL-C） as well as free fatty acid （FFA） content in liver tissue were measured； pathological changes in liver tissue were observed by hematoxylin and eosin （HE） and Oil Red O staining； serum alpha-fetoprotein （AFP） and carcinoembryonic antigen （CEA） levels were measured， and Ki-67 protein expression in liver was examined； liver lipoprotein lipase （LPL）， leukocyte differentiation antigen 36 （CD36）， carnitine palmitoyltransferase 1α （CPT1α）， B lymphocytoma-2 gene （Bcl

）， and Bcl-2 related X protein （Bax） protein expression as well as LPL， CD36 and CPT1α mRNA expression were detected.

Results

Compared to those in the normal group， the mice in the NAFLD-HCC group had liver inflammatory cell infiltration， obvious fatty degeneration， and small cell hyperplasia in certain cells； the contents of TC， TG， LDL-C， AFP and CEA significantly increased， and the content of HDL-C significantly decreased （

＜0.05 or

＜0.01）； the expression of Ki-67 protein and Bcl

protein increased， and the expression of LPL， CD36 and CPT1α mRNA and protein increased as well （

＜0.05 or

＜0.01）. In the NAFLD group， only serum TC， TG and LDL-C content significantly increased compared to those in the normal group， and only steatosis and inflammatory cell infiltration in the liver tissue were found through pathological observation； there was no significant difference in AFP and CEA content and liver Ki-67 protein expression between the two groups （

＞0.05）. Compared to those in the NAFLD-HCC group， the pathological morphology of the liver was significantly improved in the high-dose LZD group， and the area of lipid deposition was reduced； the serum TC， TG， LDL-C， AFP and CEA content decreased， while the HDL-C content increased； Ki-67 and Bcl

protein expression decreased， as well as LPL， CD36， CPT1α mRNA and protein expression （

＜0.05 or

＜0.01）； and the above indexes in high-dose LZD group were superior to those in the low- and medium-dose LZD group.

Conclusion

LZD may inhibit the occurrence and development of NAFLD-HCC by regulating fatty acid metabolism reprogramming through LPL-CD36-CPT1 metabolic axis.

关键词

Keywords

references

SUNG H ， FERLAY J ， SIEGEL RL ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］. CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

JUN TW ， YEH ML ， YANG JD ， et al . More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma ［J］. Liver Int ， 2018 ， 38 （ 5 ）： 895 - 902 .

CURRIE E ， SCHULZE A ， ZECHNER R ， et al . Cellular fatty acid metabolism and cancer ［J］. Cell Metab ， 2013 ， 18 （ 2 ）： 153 - 161 .

SATRIANO L ， LEWINSKA M ， RODRIGUES PM ， et al . Metabolic rearrangements in primary liver cancers：cause and consequences ［J］. Nat Rev Gastroenterol Hepatol ， 2019 ， 16 （ 12 ）： 748 - 766 .

XU J ， WANG R ， YOU S ， et al . Traditional Chinese medicine Lingguizhugan decoction treating non-alcoholic fatty liver disease with spleen-yang deficiency pattern：study protocol for a multicenter randomized controlled trial ［J］. Trials ， 2020 ， 21 （ 1 ）： 512 .

宋清武，李慧臻 . 加味苓桂术甘汤治疗非酒精性脂肪性肝病的临床研究［J］. 四川中医， 2013 ， 31 （ 8 ）： 60 - 62 .

FU H ， TANG B ， LANG J ， et al . High-Fat diet promotes macrophage-mediated hepatic inflammation and aggravates diethylnitrosamine-induced hepatocarcinogenesis in mice ［J］. Front Nutr ， 2020 ， 7 ： 585306 . doi： 10.3389/fnut. 2020.585306 http://dx.doi.org/10.3389/fnut.2020.585306 .

GAO J ， XIONG R ， XIONG D ， et al . The adenosine monophosphate （AMP） analog， 5-aminoimidazole-4-carboxamide ribonucleotide （AICAR） inhibits hepatosteatosis and liver tumorigenesis in a high-fat diet murine model treated with diethylnitrosamine （DEN）［J］. Med Sci Monit ， 2018 ， 24 ： 8533 - 8543 . doi： 10.12659/MSM. 910544 http://dx.doi.org/10.12659/MSM.910544 .

李美蕖，田书云，张迪 . 非酒精性脂肪肝C57BL/6J小鼠模型建立［J］. 山东化工， 2021 ， 50 （ 20 ）： 162 - 164，167 .

黄继汉，黄晓晖，陈志扬，等 . 药理试验中动物间和动物与人体间的等效剂量换算［J］. 中国临床药理学与治疗学， 2004 ， 9 （ 9 ）： 4 .

POWELL EE ， WONG VW ， RINELLA M . Non-alcoholic fatty liver disease ［J］. Lancet ， 2021 ， 397 （ 10290 ）： 2212 - 2224 .

姜家康，陈瑞睿，刘洪星，等 . 关于“肝之癌毒”理论的简述［J］. 中医药信息， 2012 ， 29 （ 4 ）： 12 - 13 .

SNAEBJORNSSON MT ， JANAKI-RAMAN S ， SCHULZE A . Greasing the wheels of the cancer machine：the role of lipid metabolism in cancer ［J］. Cell Metab ， 2020 ， 31 （ 1 ）： 62 - 76 .

LI Z ， KANG Y . Lipid metabolism fuels cancer's spread ［J］. Cell Metab ， 2017 ， 25 （ 2 ）： 228 - 230 .

LEI L ， PILO GM ， LI X ， et al . Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans ［J］. J Hepatol ， 2016 ， 64 （ 2 ）： 333 - 341 .

CAO D ， SONG X ， CHE L ， et al . Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells ［J］. Liver Int ， 2017 ， 37 （ 1 ）： 80 - 89 .

王瑾 . 肿瘤标志物AFP与CEA的联合检测在肝癌诊断中的临床价值［J］. 临床和实验医学杂志， 2011 ， 10 （ 16 ）： 2 .

MENON SS ， GURUVAYOORAPPAN C ， SAKTHIVEL KM ， et al . Ki-67 protein as a tumour proliferation marker ［J］. Clin Chim Acta ， 2019 ， 491 ： 39 - 45 . doi： 10.1016/j.cca.2019.01.011 http://dx.doi.org/10.1016/j.cca.2019.01.011 .

黄炳臣，龙喜带 . Bcl-2与Bax蛋白在肝细胞癌中的研究进展［J］. 齐齐哈尔医学院学报， 2012 ， 33 （ 3 ）： 355 - 356 .

TAO L ， DING X ， YAN L ， et al . CD36 accelerates the progression of hepatocellular carcinoma by promoting FAs absorption ［J］. Med Oncol ， 2022 ， 39 （ 12 ）： 202 .

SCHLAEPFER IR ， JOSHI M . CPT1A-mediated fat oxidation，mechanisms，and therapeutic potential ［J］. Endocrinol ， 2020 ， 161 （ 2 ）： bqz046 . doi： 10.1210/endocr/bqz046 http://dx.doi.org/10.1210/endocr/bqz046 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Impact of Intradermal Needle Therapy on Pain after Transcatheter Arterial Chemoembolization Operation of Hepatocellular Carcinoma Patients

A Preliminary Discussion on the Method of Regulating Qi and Calming the Mind

Syndrome Differentiation and Treatment of Cholinergic Urticaria from the Perspective of "Treating Fire Constraint by Dispersing It"

Research on the Correlation Between "Tiangui （天癸）" and Female Reproductive Genetic Diseases

Construction and Application of a Real-World Cohort of Community-Acquired Pneumonia Based on a Multimodal Large-Scale Traditional Chinese Medicine Big Data Platform

Related Author

WANG Tingxiang

CHEN Yidan

LOU Guoqiang

Related Institution

Second Clinical Medical College,Zhejiang Chinese Medical University

Zhejiang Hospital

Hangzhou Second People’s Hospital

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Effect of Linggui Zhugan Decoction （苓桂术甘汤） on Reprogramming of Liver Fatty Acid Metabolism in Mice Model of Hepatocellular Carcinoma Associated with Non-alcoholic Fatty Liver

DOI：10.13288/j.11-2166/r.2023.13.013

摘要

Abstract

关键词

Keywords

references